DNR:
ApprovedSmall molecule
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.DNR: is one of 51 small molecule programs targeting Adult Acute Lymphoblastic Leukemia. It is currently in Approved.
2
Indications
3
Total Trials
0
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Acute Promyelocytic Leukemia
#DrugCompanyPhaseTrials
1Idamycin
PfizerApproved
Cytosar
TevaApproved
Trisenox
CCephalon
Approved
Jakafi
IncyteApproved
Istodax
TevaApproved
Scemblix
NovartisApproved
Novantrone
EMD SeronoApproved
Cerubidine
HHikma Pharmaceuticals LLC
Approved
Trexall
Alnylam PharmaceuticalsPhase 3
Novantrone
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DNR:. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details